Similar articles

• Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.

  Mouridsen HT, Palshof T. Mouridsen HT, et al. Prog Clin Biol Res. 1977;12:459-66. Prog Clin Biol Res. 1977. PMID: 335404 Clinical Trial. No abstract available.
• Combination chemotherapy as an adjuvant treatment in operable breast cancer.

  Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U. Bonadonna G, et al. N Engl J Med. 1976 Feb 19;294(8):405-10. doi: 10.1056/NEJM197602192940801. N Engl J Med. 1976. PMID: 1246307
• The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?

  Levitt SH, Potish RA. Levitt SH, et al. Cancer Clin Trials. 1981 Winter;4(4):363-9. Cancer Clin Trials. 1981. PMID: 7032731 Review.
• Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.

  Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S. Rivkin SE, et al. Cancer. 2003 Jan 1;97(1):21-9. doi: 10.1002/cncr.10982. Cancer. 2003. PMID: 12491501 Clinical Trial.
• [Radiation and concomitant chemotherapy after surgery for breast cancer].

  Calais G. Calais G. Cancer Radiother. 2004 Feb;8(1):39-47. doi: 10.1016/j.canrad.2003.10.010. Cancer Radiother. 2004. PMID: 15093200 Review. French.